The action of the protein kinase C inhibitor, staurosporine, on human platelets. Evidence against a regulatory role for protein kinase C in the formation of inositol trisphosphate by thrombin.
The ability of several putative inhibitors of protein kinase C (PKC) to block dioctanoylglycerol (DC8)-induced phosphorylation of a 47 kDa protein (a recognized substrate for PKC) in human platelets was investigated. Staurosporine (1 microM) caused complete inhibition of phosphorylation, whereas the other reagents were either inactive (polymyxin B) or gave only partial inhibition (C-1, H-7, tamoxifen). Staurosporine (1 microM) fully inhibited the phosphorylation of the 47 kDa protein in platelets challenged with thrombin, but also inhibited the phosphorylation of a 20 kDa protein which is a substrate for myosin light-chain kinase. The inhibition of both kinases by staurosporine was associated with the inhibition of thrombin-induced secretion of ATP and 5-hydroxytryptamine and a slowing of the aggregation response; staurosporine, however, had no effect on the formation of phosphatidic acid and inositol phosphates induced by thrombin. Staurosporine also reversed the inhibitory action of phorbol esters on thrombin-induced formation of phosphatidic acid. These data are consistent with a role for these two kinases in secretion and aggregation (although there must be additional control signals, since aggregation was only slowed, not inhibited), but suggest that neither kinase is involved in the regulation of phosphoinositide metabolism. This latter conclusion contradicts previous observations that the activation of PKC by phorbol esters or membrane-permeable diacylglycerols alters the apparent activity of both phospholipase C and inositol trisphosphatase. Possible explanations for this discrepancy are discussed.
Watson
S P
SP
Department of Pharmacology, Oxford, U.K.
McNally
J
J
Shipman
L J
LJ
Godfrey
P P
PP
D000255:Adenosine Triphosphate / Q000097:blood; D000470:Alkaloids / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D006801:Humans; D015544:Inositol 1,4,5-Trisphosphate; D007295:Inositol Phosphates / Q000096:biosynthesis* / Q000097:blood; D009219:Myosin-Light-Chain Kinase / Q000037:antagonists & inhibitors / Q000097:blood; D010766:Phosphorylation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000097:blood; D012701:Serotonin / Q000097:blood; D019311:Staurosporine; D013403:Sugar Phosphates / Q000096:biosynthesis*; D013917:Thrombin / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000097:blood
D000470:Alkaloids; D001798:Blood Proteins; D007295:Inositol Phosphates; D013403:Sugar Phosphates; D012701:Serotonin; D015544:Inositol 1,4,5-Trisphosphate; D000255:Adenosine Triphosphate; D011493:Protein Kinase C; D009219:Myosin-Light-Chain Kinase; D010738:Type C Phospholipases; D013917:Thrombin; D019311:Staurosporine